Stocks making the biggest moves midday: BlackBerry, Kymera Therapeutics, Apple, Wendy's & more

Midday trading was driven by a mix of earnings beats, deal activity, and company-specific guidance, with Micron up 15% after third-quarter results topped estimates and BlackBerry rising 20% on a better-than-expected first quarter. Kymera gained 17% on Phase 2b trial enrollment, while Bio-Techne jumped 19.7% on a $73/share Merck acquisition. Offsetting the strength, Apple fell nearly 5% on price hikes, Hertz dropped more than 9% on a secondary offering, and AeroVironment slid 4% ahead of earnings and a pending restatement.

Analysis

The common thread is that the market is rewarding visible operating leverage while punishing balance-sheet or execution uncertainty. In semis, the move is not just about a strong quarter: it is a read-through that memory pricing is now feeding through to end-demand, which should expand gross margins across the supply chain for several quarters. That creates a cleaner earnings-upgrade cycle for upstream equipment and memory names than for handset or consumer hardware OEMs, where input-cost inflation is immediately visible and harder to pass through.

The bigger second-order winner is the AI/data-center capex complex. If management teams are now willing to re-anchor long-term non-handset and data-center targets higher, suppliers with exposure to NAND, storage, and process equipment can see multiple expansion even before unit revisions show up. By contrast, the hardware price increase at the consumer end is a demand-tax test: it signals margin defense, but it also risks pulling forward replacement cycles and compressing near-term units if buyers were already elastic.

The biotech move is more interesting as a platform signal than as a single-asset read-through. A successful Phase 2b enrollment inflection can re-rate adjacent names if it confirms that dermatology/immunology assets can still recruit and de-risk quickly, but the upside is fragile because this is still a multi-step probability tree with binary clinical checkpoints over 6-18 months. The travel disappointment looks more like a demand-normalization warning than a one-off miss; it suggests discretionary travel is becoming less forgiving at the margin, which is a negative tell for other OTA and leisure names with similar international mix.

The most actionable contrarian point is that the rally in the memory complex may be ahead of the forward numbers. If pricing momentum is real, consensus will rise, but the best risk/reward may actually be in the laggards that benefit from lower component costs rather than the names already up double digits. Meanwhile, the equity supply overhang in the rental and discount retail names signals that capital structure actions remain a primary overhang: these are not fundamental reratings yet, but tradable flow events that can pressure the tape for days to weeks.

Key Decisions for Investors

• Go long QCOM against AAPL for a 2-6 week relative-value trade: QCOM has both a better AI/data-center option value and less immediate margin compression from component inflation; use a 1:1.5 risk/reward with a stop on any reversal in semi breadth.
• Buy a basket long SNDK/WDC and short AAPL into the next 1-2 weeks: if memory pricing is inflecting, storage suppliers should outperform consumer hardware OEMs that are forced to absorb higher input costs; target a 10-15% relative move, cut if AAPL demand fears prove overstated.
• Initiate a small long TECH on any post-headline consolidation, with a 3-6 month horizon: clinical enrollment momentum can matter more than near-term data, but size modestly because the downside remains binary into later-stage readouts.
• Avoid chasing KYMR; instead sell upside via call spreads if liquid: the move likely priced in a lot of trial-optional upside in one session, while the key catalyst is still many months away and subject to enrollment/data risk.
• Fade HTZWW and consider a short-bias through event windows: the securities/financing overhang can cap any squeeze, and this is a flow-driven setup where the best risk/reward is on the side of supply until the financing structure clears.